Abstract
Central nervous system (CNS) tumors are the most common cause of cancer-related death in children. Despite significant treatment advances, survival rates for several tumor types (including diffuse midline glioma and other high-grade gliomas, as well as most recurrent tumors) remain poor, and current multimodal therapies, including surgery, radiation therapy, and cytotoxic chemotherapy carry a high risk of treatment-related morbidities. There is therefore a critical need to translate recent discoveries on the biological and genetic basis of pediatric CNS tumors into improvement in clinical care for these patients. Comprehensive analysis (including genome, transcriptome, and epigenome) of diverse CNS tumors has led to a heightened understanding of the spectrum and frequency of disease-specific tumorigenic genetic events underlying common pediatric tumor types, including low-grade glioma,1 high-grade glioma,2 medulloblastoma,3 and ependymoma.4 These discoveries have led to improved classification of pediatric CNS tumors through definition of key molecular events and are being successfully incorporated into the care of patients with selected tumor types. As one example, recent reports have confirmed the activity of the MEK inhibitor selumetinib for patients with both neurofibromatosis type 1 (NF1)-associated and non-NF1-associated low-grade glioma,5,6 establishing selumetinib as a therapeutic option for these patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.